Bryce Point Capital LLC Makes New $438,000 Investment in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)

Key Points

• Bryce Point Capital LLC has invested approximately $438,000 in NewAmsterdam Pharma Company by acquiring 19,653 shares in the first quarter, reflecting growing institutional interest in the stock.
• Wall Street analysts maintain a generally favorable outlook on NewAmsterdam Pharma, providing multiple buy ratings and an average target price of $41.30 for the company's shares.
• NewAmsterdam Pharma reported negative earnings in its last quarter, missing EPS estimates but surpassing revenue expectations, highlighting financial volatility amid its growth efforts in developing therapies for metabolic diseases.

Bryce Point Capital LLC bought a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 19,653 shares of the company's stock, valued at approximately $438,000.

Other institutional investors also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new position in NewAmsterdam Pharma during the fourth quarter worth approximately $50,000. National Bank of Canada FI acquired a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at $51,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of NewAmsterdam Pharma by 19.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after acquiring an additional 596 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in NewAmsterdam Pharma by 130.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock valued at $123,000 after purchasing an additional 3,390 shares during the period. Finally, Avanza Fonder AB acquired a new position in NewAmsterdam Pharma in the first quarter valued at $127,000. Institutional investors and hedge funds own 89.89% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on NAMS shares. Needham & Company LLC restated a "buy" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 target price on the stock. Stifel Nicolaus began coverage on NewAmsterdam Pharma in a report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 target price on the stock. Wall Street Zen raised NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Finally, Cantor Fitzgerald initiated coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $41.30.

Insider Buying and Selling

In other news, Director James N. Topper purchased 2,520 shares of the stock in a transaction that occurred on Tuesday, June 24th. The shares were acquired at an average price of $18.43 per share, for a total transaction of $46,443.60. Following the acquisition, the director directly owned 3,024,873 shares in the company, valued at approximately $55,748,409.39. The trade was a 0.08% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Douglas F. Kling sold 51,043 shares of the company's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $21.10, for a total value of $1,077,007.30. Following the completion of the sale, the chief operating officer directly owned 44,000 shares in the company, valued at $928,400. This trade represents a 53.71% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders purchased 12,364 shares of company stock worth $236,839 and sold 198,612 shares worth $4,025,887. Corporate insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Stock Down 1.7%

NAMS stock traded down $0.38 on Thursday, reaching $22.05. 211,772 shares of the company's stock were exchanged, compared to its average volume of 878,602. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $27.29. The firm has a market cap of $2.48 billion, a PE ratio of -11.73 and a beta of -0.03. The stock has a fifty day moving average of $20.03 and a 200-day moving average of $20.08.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. The company had revenue of $2.98 million for the quarter, compared to analyst estimates of $1.46 million. On average, equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.